Christianson Gregory J, Sun Victor Z, Akilesh Shreeram, Pesavento Emanuele, Proetzel Gabriele, Roopenian Derry C
The Jackson Laboratory; Bar Harbor, ME USA.
The Jackson Laboratory; Bar Harbor, ME USA; Current address: Barnes-Jewish Hospital; St. Louis, MO USA.
MAbs. 2012 Mar-Apr;4(2):208-16. doi: 10.4161/mabs.4.2.19397. Epub 2012 Mar 1.
The MHC class I-like Fc receptor (FcRn) is an intracellular trafficking Fc receptor that is uniquely responsible for the extended serum half-life of antibodies of the IgG subclass and their ability to transport across cellular barriers. By performing these functions, FcRn affects numerous facets of antibody biology and pathobiology. Its critical role in controlling IgG pharmacokinetics has been leveraged for the design of therapeutic antibodies and related biologics. FcRn also traffics serum albumin and is responsible for the enhanced pharmacokinetic properties of albumin-conjugated therapeutics. The understanding of FcRn and its therapeutic applications has been limited by a paucity of reliable serological reagents against human FcRn. Here, we describe the properties of a new panel of highly specific monoclonal antibodies (mAbs) directed against human FcRn with diverse epitope specificities. We show that this antibody panel can be used to study the tissue expression pattern of human FcRn, to selectively block IgG and serum albumin binding to human FcRn in vitro and to inhibit FcRn function in vivo. This mAb panel provides a powerful resource for probing the biology of human FcRn and for the evaluation of therapeutic FcRn blockade strategies.
主要组织相容性复合体I类样Fc受体(FcRn)是一种细胞内转运Fc受体,它唯一负责延长IgG亚类抗体的血清半衰期及其跨细胞屏障转运的能力。通过执行这些功能,FcRn影响抗体生物学和病理生物学的许多方面。它在控制IgG药代动力学中的关键作用已被用于治疗性抗体和相关生物制品的设计。FcRn还转运血清白蛋白,并负责白蛋白偶联治疗药物增强的药代动力学特性。由于缺乏针对人FcRn的可靠血清学试剂,对FcRn及其治疗应用的理解受到了限制。在此,我们描述了一组针对人FcRn的具有不同表位特异性的新型高特异性单克隆抗体(mAb)的特性。我们表明,该抗体组可用于研究人FcRn的组织表达模式,在体外选择性阻断IgG和血清白蛋白与人FcRn的结合,并在体内抑制FcRn功能。该mAb组为探究人FcRn的生物学特性和评估治疗性FcRn阻断策略提供了强大的资源。